John Carbona
John Carbona is the former CEO of AveXis, a biotech startup that developed Zolgensma, the groundbreaking gene therapy for spinal muscular atrophy (SMA). His leadership and management played a critical role in transitioning the therapy from research to commercialization, significantly impacting drug pricing discussions.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| United States | 1 | 5.00 | 0.02% | +0% | 331,002,651 | 58,543 | $21,000,000 | 3,714$ |
| Totals | 1 | 331,002,651 | 58,543 | $21,000,000 | 3,714$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
United States:
John Carbona was the CEO of AveXis, the biotech startup that developed Zolgensma.
5